Vincerx Pharma presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research AACR Annual Meeting 2024. “The positive preliminary data we’ve reported for VIP236 and VIP943, coupled with preclinical findings leveraging our VersAptx platform to improve the efficacy of TRODELVY and ENHERTU, two marketed ADCs, underscore the power of our platform approach for hematologic malignancies and solid tumors,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. “The early VIP236 data demonstrated positive clinical activity, including tumor reductions. This represents significant promise for patients who have exhausted standard anticancer therapy options with many different tumor types, including tumors not usually responsive to camptothecin-derived therapies. Dose escalation continues in the VIP236 and VIP943 first-in-human studies. As we advance into higher dose levels, we look forward to sharing more clinical data for VIP236 later this summer and for VIP943 on or around the 2024 European Hematology Association annual meeting.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VINC:
- Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
- Is VINC a Buy, Before Earnings?
- Vincerx Pharma to present three posters at AACR
- Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024